Prologis Inc vs Viatris Inc — how do they compare? Prologis Inc trades at $129.53 (market cap $122.87B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Prologis Inc is far larger — about 6.1× Viatris Inc's market cap, and Prologis Inc pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Prologis Inc for 102 Days and Viatris Inc for 57 Days on average.
| PLD | VTRS | |
|---|---|---|
Market Cap | $122.87B | $20.03B |
Volume | 4,222,957 | 14,109,977 |
Sector | Real Estate | Health |
52-Week High | $149.96 | $18.27 |
52-Week Low | $111.23 | $9.74 |
Typical Hold Time | 102 Days | 57 Days |
Enterprise Value | $157.61B | $32.15B |
Dividend Yield | 3.31% | 2.75% |
Signals from Pluang's Aura AI — not financial advice
Prologis (PLD) trades at $129.18, up 1.48% today, with a bearish technical signal but strong fundamentals. The stock faces near-term resistance at $130, with support at $127. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $1.13 versus $0.747 expected. Revenue grew to $8.79B in 2025, and net income margin remains robust at 45.79%. The company benefits from strong warehouse demand driven by e-commerce and data centers, as highlighted in recent news.
Outlook is positive with a consensus price target of $155.15, implying 20% upside, supported by 59.5% analyst buy ratings. Risks include rising debt-to-asset ratio (37.2% in 2025) and macroeconomic sensitivity. Institutional interest is strong, with QRG Capital increasing holdings by 11% in Q2 2026. The dividend yield of approximately 0.83% adds income appeal, but investors should monitor leverage and interest rate impacts.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →